Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXA-BYW.10 in seasonal influenza B
NCT02547792Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Oct 2015
- Primary completion
- Nov 2016
- Modality
- Prophylactic Vaccines, Adenoviral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VXA-BYW-10 in influenza B (3 arms), sponsored by Vaxart, Inc. Primary endpoint: Safety and Tolerability of Single High Dose of an Oral Influenza B Tablet Vaccine at Day 28. Started Oct 2015; status: completed.
02
Drugs
VXA-BYW-10
03
Conditions
influenza B
Beyond the preview
Go deeper on NCT02547792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547792.